---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/38819266.md"
description: "What you said is true, I'll just add two points:1. The weight-loss drug market is a blue ocean with demand exceeding supply. Eli Lilly's production capacity cannot swallow the entire market, and the high entry barriers make it difficult for new manufacturers to enter.2. Novo Nordisk's semaglutide has FDA-approved cardiovascular prevention and kidney disease delay effects, which is why federal Medicare and other national health insurance plans can cover it.$Novo Nordisk AS(NVO.US)"
datetime: "2026-02-22T06:54:59.000Z"
locales:
  - [en](https://longbridge.com/en/topics/38819266.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/38819266.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/38819266.md)
author: "[艾萨克·牛顿](https://longbridge.com/en/profiles/15057684.md)"
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/topics/38819266.md) | [繁體中文](https://longbridge.com/zh-HK/topics/38819266.md)


# What you said is true, I'll just add two points:1.…


### Related Stocks

- [Novo Nordisk A/S (NVO.US)](https://longbridge.com/en/quote/NVO.US.md)
- [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md)